Metastatic Gastric Cancer

Oncology
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Virogin Biotech
Virogin BiotechBC - Richmond
1 program
1
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 InjectionPhase 1/21 trial
Active Trials
NCT06008925RecruitingEst. Jun 2026
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
Didactic SessionN/A1 trial
Active Trials
NCT04618809Unknown100Est. Dec 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Virogin BiotechRecombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection
Eli Lilly and CompanyDidactic Session

Clinical Trials (2)

Total enrollment: 100 patients across 2 trials

NCT06008925Virogin BiotechRecombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection

Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer

Start: Nov 2022Est. completion: Jun 2026
Phase 1/2Recruiting

Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer

Start: Sep 2020Est. completion: Dec 2023100 patients
N/AUnknown

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 100 patients
2 companies competing in this space